294 related articles for article (PubMed ID: 21343372)
1. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
Mohamedali KA; Ran S; Gomez-Manzano C; Ramdas L; Xu J; Kim S; Cheung LH; Hittelman WN; Zhang W; Waltenberger J; Thorpe PE; Rosenblum MG
BMC Cancer; 2011 Aug; 11():358. PubMed ID: 21849059
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
5. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
[TBL] [Abstract][Full Text] [Related]
6. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
Huang S; He P; Peng X; Li J; Xu D; Tang Y
Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
[TBL] [Abstract][Full Text] [Related]
7. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
8. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.
Ran S; Mohamedali KA; Luster TA; Thorpe PE; Rosenblum MG
Neoplasia; 2005 May; 7(5):486-96. PubMed ID: 15967101
[TBL] [Abstract][Full Text] [Related]
9. Light-enhanced VEGF
Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
[TBL] [Abstract][Full Text] [Related]
10. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
[TBL] [Abstract][Full Text] [Related]
11. BMP4 promotes prostate tumor growth in bone through osteogenesis.
Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
[TBL] [Abstract][Full Text] [Related]
12. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Veenendaal LM; Jin H; Ran S; Cheung L; Navone N; Marks JW; Waltenberger J; Thorpe P; Rosenblum MG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):7866-71. PubMed ID: 12060733
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β2AR-Dependent Neo-Angiogenic Switch.
Mulcrone PL; Campbell JP; Clément-Demange L; Anbinder AL; Merkel AR; Brekken RA; Sterling JA; Elefteriou F
J Bone Miner Res; 2017 Jul; 32(7):1442-1454. PubMed ID: 28300321
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
